Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Celldex Therapeutics (CLDX) over the last 15 years, with Q3 2025 value amounting to 0.41%.

  • Celldex Therapeutics' Return on Capital Employed fell 1800.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.33% for FY2024, which is 800.0% up from last year.
  • Celldex Therapeutics' Return on Capital Employed amounted to 0.41% in Q3 2025, which was down 1800.0% from 0.34% recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Return on Capital Employed ranged from a high of 0.16% in Q4 2021 and a low of 0.51% during Q3 2023
  • Over the past 5 years, Celldex Therapeutics' median Return on Capital Employed value was 0.3% (recorded in 2025), while the average stood at 0.31%.
  • In the last 5 years, Celldex Therapeutics' Return on Capital Employed plummeted by -2200bps in 2023 and then soared by 2800bps in 2024.
  • Celldex Therapeutics' Return on Capital Employed (Quarter) stood at 0.16% in 2021, then tumbled by -106bps to 0.34% in 2022, then crashed by -34bps to 0.45% in 2023, then surged by 44bps to 0.25% in 2024, then tumbled by -62bps to 0.41% in 2025.
  • Its Return on Capital Employed was 0.41% in Q3 2025, compared to 0.34% in Q2 2025 and 0.3% in Q1 2025.